Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 65 years old who are considered suitable candidates for a stem cell transplant
- People diagnosed with very high-risk multiple myeloma whose disease either did not respond well enough, or stopped responding, to a standard first-line treatment regimen (VRD-based therapy), with or without certain high-risk genetic features in their cancer cells
- People whose liver, kidneys, bone marrow, and heart are functioning at an adequate level
- People who are generally well enough to carry out daily activities with little to no limitation (based on a standard medical fitness scale called ECOG, scoring 0 or 1)
- People who are capable of having children and who agree to use contraception throughout the study period
Who may not be able to join:
- People with a known allergy to any ingredient in the C-CAR088 cell treatment being studied
- People who have previously had a donor stem cell transplant or their own stem cell transplant
- People whose multiple myeloma has spread to the central nervous system (brain or spinal cord)
- People who have had a stroke or seizure within the 6 months before signing the study consent form
- People with an autoimmune disease, a weakened immune system, or any condition that requires them to take immune-suppressing medications
- People with an active infection that is not under control, or an active hepatitis B, hepatitis C, HIV, or syphilis infection
- People with serious heart, liver, kidney, or metabolic disease
- People who have not waited long enough after their last cancer treatment before the cell collection process (apheresis) can take place
- People who have previously received CAR-T cell therapy, other genetically modified T-cell treatments, or any treatment targeting a protein called BCMA
- People with any other medical condition, ongoing therapy, or abnormal test result that, in the investigator's judgement, could affect the safety or results of the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dehui Zou, M.D., PH.D., Institute of Hematology & Blood Diseases Hospital, China
Phone: 86-022-23909171
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence rate and severity of adverse events (AE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.